How can we accelerate and improve drug development? By improving the methodologies we use along the way. While animal- or cell-based studies are currently the standard for preclinical trials, they are simply not effective enough. After all, clinical trials often fail because preclinical trials didn’t provide enough insight. TNO’s Organ-on-a-Chip (OoaC) technologies offer a better solution. We use human cells or tissue for faster, more accurate results.
Fewer animals, more humans
Pharma and biotech companies understand the limitations of animal testing. Although they can provide initial indications of drug interactions or efficacy, clinical results often do not match the results obtained from preclinical studies. With ethical questions related to animal testing driving the industry to search for better solutions, OoaC can be a viable alternative. It accurately mimics human organ functionalities to predict absorption, distribution, metabolism and excretion (ADME) and/or efficacy of medical compounds in preclinical phase, and moreover provide deeper insights into how interventions can impact human health.
Kristel Adriaenssens Milet 1 April 2025 Social intelligence company Dynvibe, which specialises in behavioural marketing…
26 March 2025 The 35th IFSCC Congress will take place in Cannes from September 15…
This AI-powered skin diagnostic device uses bio-optical technology alongside AI algorithms to analyze the skin’s…